DDInter117 DDInter808
Argatroban is a direct, selective thrombin inhibitor. The American College of Cardiologists (ACC) recommend using bivalirudin or argatroban in patients who have had, or at risk for, heparin induced thrombocytopenia (HIT) and are undergoing percutaneous coronary intervention. Argatroban is a non-heparin anticoagulant shown to both normalize platelet count in patients with HIT and prevent the formation of thrombi. Parental anticoagulants must be stopped and a baseline activated partial thromboplastin time must be obtained prior to administering argatroban.
Garlic allergenic extract is used in allergenic testing.
Argatroban {u} (Compound) binds {v} (Gene) CYP3A4
Argatroban {u} (Compound) is included by {v} (Pharmacologic Class) Thrombin Inhibitors
Argatroban {u} (Compound) causes {v} (Side Effect) Haemorrhage
Argatroban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Clove
Argatroban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Choline salicylate
Argatroban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Alemtuzumab
Argatroban {u} may lead to a major life threatening interaction when taken with {v} Streptokinase
Argatroban {u} may lead to a major life threatening interaction when taken with {v} Danaparoid
Argatroban (Compound) binds CYP3A4 (Gene)
Argatroban (Compound) is included by Thrombin Inhibitors (Pharmacologic Class)
Argatroban (Compound) causes Haemorrhage (Side Effect)
Argatroban may cause a minor interaction that can limit clinical effects when taken with Clove
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Choline salicylate
Argatroban may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab
Argatroban may lead to a major life threatening interaction when taken with Streptokinase
Argatroban may lead to a major life threatening interaction when taken with Danaparoid